• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan

    7/26/24 9:05:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email

    Those Who Previously Voted "No" Can Still Switch Their Vote to "Yes"

    Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson ("J&J") (NYSE:JNJ) talcum powder settlement, leaving claimants just hours to act.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726806059/en/

    Haven't voted in favor of the talcum powder plan yet? There's still time. (Graphic: Business Wire)

    Haven't voted in favor of the talcum powder plan yet? There's still time. (Graphic: Business Wire)

    Talc claimants can vote on the plan at www.OfficialTalcClaims.com or by calling 1-888-431-4056.

    The approximately $8 billion plan, which has a net present value of $6.475 billion, will compensate current and future claimants who were harmed by J&J's talcum powder products, putting an end to a lengthy, frustrating litigation process. Under the plan, ovarian cancer claimants are expected to receive an average of $75,000 to $150,000 each.

    In order for claimants and families to achieve the timely and fair compensation they deserve, at least 75% of the people casting votes must vote YES on the plan.

    The Ad Hoc Group of Counsel – representing more than 77,500 individuals in this matter – urges all individuals harmed by J&J baby powder products and their attorneys to take action now before the deadline of 5pm ET today.

    If you have already voted "no" and are having second thoughts, it's not too late: Only your latest vote counts and will override any prior vote you cast. Please know that your voting decision is completely confidential.

    The Ad Hoc Group of Counsel believes that law firms opposing the settlement have attempted to sway voters towards continued litigation, because doing so would result in hundreds of millions of dollars in fees to the lawyers. Those extra payments to attorneys would not be available through a bankruptcy settlement.

    At this critical time, the Ad Hoc Group of Counsel is providing detailed responses to the misleading claims put forth by opposing law firms so that all J&J claimants can make an informed voting decision.

    • What They Claim: There is no way of knowing how much claimants will be paid or when.

      The Truth: Under the J&J bankruptcy plan, ovarian cancer claimants are projected to receive an average recovery of between $75,000 and $150,000.
    • What They Claim: Claimants are being deprived of the right to choose to settle.

      The Truth: By voting on J&J's bankruptcy plan, people are actually making their voice heard and preserving their ability to participate in this historic settlement of approximately $8 billion through a process that eliminates litigation risk.
    • What They Claim: Claimants have a better chance of succeeding if they vote "no" and take their case to trial.

      The Truth: In over a decade of litigation, just 17 ovarian cancer cases have gone to trial. J&J and its subsidiaries have prevailed in 16 of those cases, with plaintiffs recovering no money.
    • What They Claim: Resolution through multidistrict litigation (MDL) is the fairest way to handle these cases.

      The Truth: The law firms opposing the settlement have had ample time to reach a resolution through MDL, but their efforts to reach a consensus have not been successful.
    • What They Claim: There are thousands of "fantasy cases" among those voting to support the plan.

      The Truth: Our clients are real people who have suffered greatly as a result of using J&J talc products. This statement is deeply offensive to the tens of thousands of talc victims represented by the Ad Hoc Group of Counsel.
    • What They Claim: People diagnosed with ovarian cancer in the future due to their past use of talc products won't be able to hold J&J accountable.

      The Truth: A future claims representative is representing the rights of future claimants, and those future victims will have the same recovery rights as current claimants.
    • What They Claim: Voting against the plan will make J&J suffer.

      The Truth: Voting "no" hurts victims, not J&J. If the proposed plan fails to garner enough "yes" votes, these victims will not receive compensation for their suffering for years, if ever.
    • What They Claim: If J&J is able to resolve this matter through bankruptcy, other corporations will also seek to escape mass tort liability and jury trials through the bankruptcy process.

      The Truth: If this vote succeeds, J&J will be paying an historic amount - approximately $8 billion - to settle claims. The company is being held accountable for the harm its products caused.

    Ovarian cancer survivor Tamika Evans, 47, of Chicago voted to approve the plan. She stated: "I support this settlement because I need help with my ongoing treatment costs and to recover from the medical debt. It's about more than money – it's about acknowledging the impact on our lives."

    As Anna Maria Sanderford, 61, of Arizona, stated: "We need to get this settlement done so we can go on with our lives and do what we want with the time we have left."

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240726806059/en/

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    11/13/2025$230.00Sector Outperform
    Scotiabank
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    7/23/2025Hold → Buy
    Erste Group
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    More analyst ratings

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP Corporate Controller Decker Robert J exercised 4,075 shares at a strike of $115.67 and sold $1,010,070 worth of shares (4,075 units at $247.87) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/3/26 4:21:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, WW Chair, MedTech Schmid Timothy sold $324,763 worth of shares (1,322 units at $245.66), decreasing direct ownership by 5% to 25,447 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/23/26 5:20:21 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CIO Swanson James D. sold $15,109,759 worth of shares (62,080 units at $243.39), exercised 73,140 shares at a strike of $139.50 and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 36% to 25,698 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:32 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

    Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression–free survival and overall survival versus standard of care regimens83.3% of patients were alive at three years, indicating durable clinical benefitHORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteaso

    3/5/26 3:55:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

    GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

    3/5/26 9:30:00 AM ET
    $ACHC
    $AIFF
    $BWAY
    Medical Specialities
    Health Care
    Computer Software: Prepackaged Software
    Technology

    /C O R R E C T I O N -- Johnson & Johnson/

    In the news release, Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE), issued 03-Mar-2026 by Johnson & Johnson over PR Newswire, we are advised by the company that the last sentence of the fifth paragraph has been amended. The complete, corrected release follows: Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timelineThe designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity

    3/3/26 8:03:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    SEC Filings

    View All

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/13/26 4:24:01 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Johnson & Johnson

    10-K - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 4:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Johnson & Johnson reports Q4 and Full-Year 2025 results

    2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisition of Halda Therapeutics 2025 Full-Year reported sales growth of 6.0% to $94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of $11.03 and adjusted EPS of $10.79, both include $(0.10) due to the acquisition of Halda Therapeutics Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for

    1/21/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care